Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer

Kim, Sun Hwa; Jeong, Ji Hoon; Lee, Soo Hyun; Kim, Sung Wan; Park, Tae Gwan

doi:10.1016/j.jconrel.2008.03.008

Cited by 335 publications

(235 citation statements)

References 48 publications

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“…The emergence of RNAi as a unique endogenous powerful cellular mechanism which triggered downregulation of specific gene expression, propelled a flurry of research activities in the fields of biotechnology. Since then, the impetus to unravel the plethora of opportunities in the siRNA-mediated therapy triggers significant advancement in the treatment of various disease targets, including viral infections (Morrissey et al, 2005, Okumura et al, 2008 and cancers (Ptasznik et al, 2004;Xia et al, 2007;Kim et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Polymers in Small-Interfering RNA Delivery

Singha

Namgung

Kim

2011

Nucleic Acid Therapeutics

179

107

View full text Add to dashboard Cite

This review will cover the current strategies that are being adopted to efficiently deliver small interfering RNA using nonviral vectors, including the use of polymers such as polyethylenimine, poly(lactic-co-glycolic acid), polypeptides, chitosan, cyclodextrin, dendrimers, and polymers-containing different nanoparticles. The article will provide a brief and concise account of underlying principle of these polymeric vectors and their structural and functional modifications which were intended to serve different purposes to affect efficient therapeutic outcome of small-interfering RNA delivery. The modifications of these polymeric vectors will be discussed with reference to stimuli-responsiveness, target specific delivery, and incorporation of nanoconstructs such as carbon nanotubes, gold nanoparticles, and silica nanoparticles. The emergence of small-interfering RNA as the potential therapeutic agent and its mode of action will also be mentioned in a nutshell.

show abstract

Section: Introductionmentioning

confidence: 99%

Polymers in Small-Interfering RNA Delivery

Singha

Namgung

Kim

2011

Nucleic Acid Therapeutics

179

107

View full text Add to dashboard Cite

show abstract

“…Various promising nanoparticles (NPs) strategies that have been successful in depicting in vitro gene silencing and tumor reduction efficacy in animal models, safety in non-human primates and in few cases, have undergone clinical trial testing include, (A) Lipid based NPs: liposomes [16], lipoplexes [17,18], stable nucleic acid lipid nanoparticles (SNALP) [19,20] & lipidoid [21], polycation liposomes [22,23], (B) Polymeric NPs: both natural and synthetic, includes cyclodextrin [24], chitosan [25], PLGA [26], polymeric micelles [27], PEI [28] & dendrimers [29], (C) Inorganic NPs: calcium phosphate CaP [30], (D) Carbon-based materials, carbon nanotubes (SWNTs, MWNTs) [31,32], (E) Metal nanoparticles -Gold (Au) [33], Quantum dots (QDs) [34], silicon-based nanoparticles (MSNPs) [35] & super paramagnetic iron oxide nanoparticles (SPIONs) [36] etc. In addition to this, atelocollagen-based delivery strategy also proved to be successful in few cases [37,38].…”

Section: Nanotechnology-based Delivery Strategiesmentioning

confidence: 99%

RNAi-based Cancer Therapeutics: Are we there yet?

Saxena¹

2014

J Pharmacovigil

View full text Add to dashboard Cite

RNAi-based therapeutics remains one of the most promising strategies for the effective cancer treatment due to its high target-specificity, precise mechanism of action, greater potency and reduced side effects. Although, tremendous progress and advances have been made in the past few years to develop nanotechnology-based efficient non-viral delivery systems, there are still many hurdles and challenges that must be conquered to achieve the target of clinically relevant formulation in terms of safety, specificity and efficacy.

show abstract

“…ABC particles are especially beneficial for passive targeting delivery, in light of the leaky endothelial wall (~400nm) in inflammatory and tumour sites resulting in the EPR effect as described above. Kim and colleagues [114] utilized PEG-conjugated VEGF siRNA (siRNA-PEG) and PEI to spontaneously form nanoscale polyelectrolyte complex micelles, having a siRNA/PEI inner core with a surrounding PEG shielding layer. Intravenous administration of this formulation successfully inhibited VEGF expression and tumour development in a tumour-bearing mouse model.…”

Section: "Abc" System -Based Deliverymentioning

confidence: 99%

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery

et al. 2010

View full text Add to dashboard Cite

Access to the full text of the published version may require a subscription. Rights AbstractGene silencing using RNA-interference, first described in mammalian systems almost a decade ago, is revolutionizing therapeutic target validation efforts both in vitro and in vivo. Moreover, the potential for using short interfering RNA (siRNA) as a therapy in its own right is also progressing at a significant pace. However, the widespread use of such approaches is contingent on having appropriate delivery systems to achieve clinically appropriate, safe, and efficient delivery of siRNA. There are many physicochemical and biological barriers to such delivery, and a growing emphasis on the design and characterisation of non-viral technologies that will overcome these barriers and expedite targeted delivery. This review discusses the considerations and challenges associated with use of siRNA-based therapeutics, including stability and off-target effects. Speculation is made on the properties of an ideal delivery system and the non-viral delivery approaches used to date, both in vitro and in vivo, are classified and discussed. Moreover, the ability of cyclodextrin-based delivery vectors to fulfil many of the criteria of an ideal delivery construct is also elaborated.3 Introduction:

show abstract

Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer

Cited by 335 publications

References 48 publications

Polymers in Small-Interfering RNA Delivery

Polymers in Small-Interfering RNA Delivery

RNAi-based Cancer Therapeutics: Are we there yet?

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery

Contact Info

Product

Resources

About